<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359903</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-055-1/ASART-1</org_study_id>
    <nct_id>NCT02359903</nct_id>
  </id_info>
  <brief_title>Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis</brief_title>
  <official_title>International Multicenter Comparative Double Blind Study of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASART-1 clinical study is a phase 1 study which carried out to establish the pharmacokinetic
      equivalence and equal safety profile of BCD-055 (infliximab manufactured by JSC BIOCAD,
      Russia) and Remicade when used as multiple IV infusions for the treatment of ankylosing
      spondylitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASART-1 study is the first step of clinical evaluation of infliximab biosimilar manufactured
      by JSC BIOCAD, Russia.The aim of this study is to establish that BCD-055 is equivalent to
      Remicade in terms of pharmacokinetics and safety when used by the standard regimen in
      patients with ankylosing spondylitis (AS).

      The study will enroll 90 patients with active AS, who will be randomized into 2 groups (1:1
      ratio): patients from the first group will receive BCD-055 IV at a dose 5 mg/kg on week 0, 2,
      6, 14 and 22; patients from the second group will receive Remicade at the same regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 336 Hours After the Single Infusion of BCD-055/Remicade</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of Infliximab After the Single Infusion of BCD-055/Remicade</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patients who received at least 1 injection. From BCD-055 group 1 patient was excluded because of violation of timing of blood collection. From Remicade group 2 patients were excluded due to AE/SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration of Infliximab After the Single Infusion of BCD-055/Remicade</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of Infliximab After the 1st, 2nd, 3rd, 4th and 5th Infusion of BCD-055/Remicade</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Concentration of Infliximab After the 1st, 2nd, 3rd, 4th and 5th Infusion of BCD-055/Remicade</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration of Infliximab After the1st, 2nd, 3rd, 4th and 5th Infusion of BCD-055/Remicade</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half Life of Infliximab After the 1st and 5th Infusion of BCD-055/Remicade</measure>
    <time_frame>2 weeks / 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration of Infliximab at Steady State Phase</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group Achieving ASAS20</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group Achieving ASAS40</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of BASDAI Score Compared With Baseline</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of BASMI Score Compared With Baseline</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of BASFI Score Compared With Baseline</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of MASES Score Compared With Baseline</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of SF36 Score Compared With Baseline</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Chest Expansion Compared With Baseline</measure>
    <time_frame>14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE After the Single Infusion of BCD-055/Remicade</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Frequency of AE/SAE Within the Whole Time of the Study</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Frequency of Grade 3-4 Laboratory Abnormalities Within the Whole Time of the Study</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected</measure>
    <time_frame>screening / 14 weeks / 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Early Withdrawal Due to AE/SAE</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum Concentration at Steady State</measure>
    <time_frame>28 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Plasma Concentration-time Curve at Steady State Phase</measure>
    <time_frame>28 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>BCD-055 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab (BCD-055)</intervention_name>
    <description>infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha</description>
    <arm_group_label>BCD-055 group</arm_group_label>
    <other_name>Remicade</other_name>
    <other_name>BCD-055</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab (Remicade)</intervention_name>
    <arm_group_label>Remicade group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  active ankylosing spondylitis, which exists in patient within last 3 months

          -  BASDAI score &gt; or equal to 4 points, spinal pain (by VAS) &gt; or equal to 4 points

          -  history of NSAID use for the treatment of AS within last 3 months

          -  adequate renal and liver function

          -  absence of severe abnormalities in complete blood count

          -  consent to use adequate contraception

          -  ability to follow Protocol procedures

        Exclusion Criteria:

          -  previously use of any biologic for AS treatment

          -  total ankylosing of the spine

          -  known allergy to chimeric proteins or any excipients of BCD-055/Remicade

          -  hepatitis B, active hepatitis C, HIV, syphilis

          -  known tuberculosis

          -  latent forms of tuberculosis

          -  any bacterial infection diagnosed within last month which required oral antibiotics
             (within last 2 weeks) or parenteral antibiotics (within last 4 weeks)

          -  drug or alcohol abuse

          -  any other disease which can affect assessments or masking some symptoms of AS (severe
             osteoarthrosis, nervous disorders with impairment of sensory or motor functions,
             another inflammatory joint disease apart from AS, etc.)

          -  severe uncontrolled hypertension

          -  chronic heart failure

          -  decompensated renal or liver disorders

          -  severe uncontrolled diabetes mellitus

          -  chronic obstructive lung disease, atopic bronchial asthma, angioedema in anamnesis

          -  any mental disorder, incl. severe depression or/and suicide thoughts/actions in
             anamnesis

          -  unstable angina pectoris

          -  myocardial infarction within last 12 months

        Other exclusion criteria could be found in the Full Study Protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivanov Roman, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Rheumotology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhegorodskaya Regional Clinical Hospital named after N.A. Semashko</name>
      <address>
        <city>N.Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local hospital at the station Smolensk OAO RZD</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University n.a. I.I.Mechnikov</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <results_first_submitted>April 3, 2016</results_first_submitted>
  <results_first_submitted_qc>May 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2016</results_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-055 Group</title>
          <description>BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (BCD-055): infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha</description>
        </group>
        <group group_id="P2">
          <title>Remicade Group</title>
          <description>Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (Remicade)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who received at least 1 injection of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>BCD-055 Group</title>
          <description>BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (BCD-055): infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha</description>
        </group>
        <group group_id="B2">
          <title>Remicade Group</title>
          <description>Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (Remicade)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="32" upper_limit="51"/>
                    <measurement group_id="B2" value="38" lower_limit="35" upper_limit="55"/>
                    <measurement group_id="B3" value="38" lower_limit="33" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 336 Hours After the Single Infusion of BCD-055/Remicade</title>
        <time_frame>2 weeks</time_frame>
        <population>Patients who received at least 1 injection. From BCD-055 group 1 patient was excluded because of violation of timing of blood collection. From Remicade group 2 patients were excluded due to AE/SAE.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-055 Group</title>
            <description>BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (BCD-055): infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha</description>
          </group>
          <group group_id="O2">
            <title>Remicade Group</title>
            <description>Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (Remicade)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 336 Hours After the Single Infusion of BCD-055/Remicade</title>
          <population>Patients who received at least 1 injection. From BCD-055 group 1 patient was excluded because of violation of timing of blood collection. From Remicade group 2 patients were excluded due to AE/SAE.</population>
          <units>(ng/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26282582" lower_limit="21094742" upper_limit="32296361"/>
                    <measurement group_id="O2" value="25914888" lower_limit="20105020" upper_limit="32661812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration of Infliximab After the Single Infusion of BCD-055/Remicade</title>
        <description>Patients who received at least 1 injection. From BCD-055 group 1 patient was excluded because of violation of timing of blood collection. From Remicade group 2 patients were excluded due to AE/SAE.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-055 Group</title>
            <description>BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (BCD-055): infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha</description>
          </group>
          <group group_id="O2">
            <title>Remicade Group</title>
            <description>Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (Remicade)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration of Infliximab After the Single Infusion of BCD-055/Remicade</title>
          <description>Patients who received at least 1 injection. From BCD-055 group 1 patient was excluded because of violation of timing of blood collection. From Remicade group 2 patients were excluded due to AE/SAE.</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174638" lower_limit="139415" upper_limit="239141"/>
                    <measurement group_id="O2" value="195434" lower_limit="134622" upper_limit="257656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Concentration of Infliximab After the Single Infusion of BCD-055/Remicade</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration of Infliximab After the 1st, 2nd, 3rd, 4th and 5th Infusion of BCD-055/Remicade</title>
        <time_frame>28 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Concentration of Infliximab After the 1st, 2nd, 3rd, 4th and 5th Infusion of BCD-055/Remicade</title>
        <time_frame>28 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Concentration of Infliximab After the1st, 2nd, 3rd, 4th and 5th Infusion of BCD-055/Remicade</title>
        <time_frame>28 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half Life of Infliximab After the 1st and 5th Infusion of BCD-055/Remicade</title>
        <time_frame>2 weeks / 28 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration of Infliximab at Steady State Phase</title>
        <time_frame>28 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group Achieving ASAS20</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group Achieving ASAS40</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of BASDAI Score Compared With Baseline</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of BASMI Score Compared With Baseline</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of BASFI Score Compared With Baseline</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of MASES Score Compared With Baseline</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of SF36 Score Compared With Baseline</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of Chest Expansion Compared With Baseline</title>
        <time_frame>14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of AE/SAE After the Single Infusion of BCD-055/Remicade</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Frequency of AE/SAE Within the Whole Time of the Study</title>
        <time_frame>30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Frequency of Grade 3-4 Laboratory Abnormalities Within the Whole Time of the Study</title>
        <time_frame>30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected</title>
        <time_frame>screening / 14 weeks / 30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Early Withdrawal Due to AE/SAE</title>
        <time_frame>30 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Concentration at Steady State</title>
        <time_frame>28 weeks</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Plasma Concentration-time Curve at Steady State Phase</title>
        <time_frame>28 weeks</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BCD-055 Group</title>
          <description>BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (BCD-055): infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha</description>
        </group>
        <group group_id="E2">
          <title>Remicade Group</title>
          <description>Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
Infliximab (Remicade)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biryulin Andrey</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7812380 49 33 ext 925</phone>
      <email>biryulin@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

